[HTML][HTML] Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell …
Y Shi, G Chen, X Wang, Y Liu, L Wu, Y Hao… - The Lancet …, 2022 - thelancet.com
Background Furmonertinib (AST2818) is an irreversible, selective, third-generation EGFR
tyrosine-kinase inhibitor. We aimed to investigate the efficacy and safety of furmonertinib …
tyrosine-kinase inhibitor. We aimed to investigate the efficacy and safety of furmonertinib …
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung …
Y Shi, G Chen, X Wang, Y Liu, L Wu, Y Hao… - The Lancet …, 2022 - europepmc.org
Background Furmonertinib (AST2818) is an irreversible, selective, third-generation EGFR
tyrosine-kinase inhibitor. We aimed to investigate the efficacy and safety of furmonertinib …
tyrosine-kinase inhibitor. We aimed to investigate the efficacy and safety of furmonertinib …
Furmonertinib (AST2818) Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multi …
Y Shi, G Chen, X Wang, Y Liu, L Wu, Y Hao, C Liu… - papers.ssrn.com
Background: Furmonertinib (AST2818) is an irreversible, selective third-generation
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). We compared the …
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). We compared the …
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung …
Y Shi, G Chen, X Wang, Y Liu, L Wu, Y Hao… - The Lancet Respiratory …, 2022 - Elsevier
Background Furmonertinib (AST2818) is an irreversible, selective, third-generation EGFR
tyrosine-kinase inhibitor. We aimed to investigate the efficacy and safety of furmonertinib …
tyrosine-kinase inhibitor. We aimed to investigate the efficacy and safety of furmonertinib …
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung …
Y Shi, G Chen, X Wang, Y Liu, L Wu… - The Lancet …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Furmonertinib (AST2818) is an irreversible, selective, third-generation EGFR
tyrosine-kinase inhibitor. We aimed to investigate the efficacy and safety of furmonertinib …
tyrosine-kinase inhibitor. We aimed to investigate the efficacy and safety of furmonertinib …